Slide 1: Dimerix: Introducing DMX-200 for ARDS in COVID-19
Dimerix A clinical stage biotech with a scalable, proprietary platform technology Introducing DMX-200 for Acute Respiratory Distress Syndrome in patients with COVID-19 04 June 2020
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: For personal use only
For personal use only • • • • • • 3
Slide 4: Share price performance
For personal use only Share price performance 4 *Inclusive of R&D tax advance received Apr20
Slide 5: For personal use only
For personal use only James Williams Nina Webster Hugh Alsop Sonia Poli Robert Shepherd PhD, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD PhD Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director R & D Director iCeutica, Yuuwa, AdAlta, Polyactiva Wyeth (Pfizer),
Slide 6: Product candidates in the pipeline with clinical read outs expected
For personal use only 4 product candidates in the pipeline, with 3 clinical read outs expected in coming months Pivotal Study Preclinical Phase 2 Phase 1 Market Compound Disease Target Acute Respiratory Distress Syndrome DMX-200 (ARDS) in COVID-19 patients Focal Segmental Glomerulosclerosis Phase 2
Slide 7: DMX-200 for Acute Respiratory Distress Syndrome in patients with COVID-19
DMX-200 for Acute Respiratory Distress Syndrome in patients with COVID-19 ae
Slide 8: For personal use only
• • • • For personal use only • • • 8
Slide 9: Current ARDS Management
Current ARDS Management Rescue Therapies In patients who continue to deteriorate so-called rescue therapies may be needed, e.g. extracorporeal blood gas exchange Respiratory support The volume of gas, concentration of oxygen and tl ressure at which it is delivered must be optimised to facilitate ade
Slide 10: Current COVID-19 Studies
Current COVID-19 Studies No products currently marketed to prevent or treat Significant interest in disruption of the renin-angiotensin -——— COVID-19 or ARDS system (RAS) Studies underway for, Number of studies are investigating angiotensin receptor blockers (ARBs) to reduce cytokine storm demonstra
Slide 11: REMAP-CAP
REMAP-CAP Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) REMAP-CAP REMAP-CAP: global WHO. endorsed clinical study; >200 clinical sites* REMAP-CAP has been designated by the WHO as a Pandemic Special Study* translation of clinical trial resul
Slide 12: For personal use only
For personal use only • • • • • • 12
Slide 13: ARDS Mechanism of Action
ARDS Mechanism of Action Chemokines including MCP-1 DMX-200 stops ° cells leaving blood 68 8a and moving into lung DMX-200 stops key ro eo eee. 7 inflammatory signals (MCP-1) from being recognized by immune cells — stopping them moving to the lung and causing ARDS fi t ° Reduced immune cells in lung
Slide 14: REMAP-CAP clinical study domains
REMAP-CAP clinical study domains REMAP-CAP study has several existing treatment domains including: » COVID-19 Anti-viral Domain * COVID-19 Immune Modulation Domain * COVID-19 Immunoglobulin Domain A COVID-19 Inflammatory treatment arm is being established, which plans to include DMX-200 @w Dimerix 1
Slide 15: REMAP-CAP adaptive design concept
REMAP-CAP adaptive design concept * Recruits patients with ARDS associated with COVID-19, who require hospitalisation and/or ICU care for the support of organ functions* ¢ Uses an innovative adaptive study design to efficiently evaluate multiple interventions simultaneously* Eligible Randomise to in
Slide 16: DMX-200 Chemistry, Manufacturing and Control (CMC)
DMX-200 Chemistry, Manufacturing and Control (CMC) bem 2 a2 US based contract FDA approved manufacturing US based manufacturer manufacturer appointed for facility engaged for finished product commercial API supply manufacture Ce e O a ay Analytical methods validated Commercial scale GMP batch Exclus
Slide 17: For personal use only
For personal use only • • • • • 17
Slide 18: Assets 100% owned by Dimerix
For personal use only Assets 100% owned by Dimerix 18
Slide 19: Study funding
Study funding REMAP-CAP study supported and funded by a consortium of government and non-government organisations* Dimerix will work with REMAP-CAP to rapidly obtain the necessary regulatory & ethics approvals Following such approval, it is anticipated that Dimerix will: e supply DMX-200 to clinical
Slide 20: For personal use only
• • • • • For personal use only 20
Slide 21: DMX-200 for Kidney Disease
ae DMX-200 for Kidney Disease
Slide 22: Two Phase studies: DMX-200 in kidney disease
Two Phase 2 studies: DMX-200 in kidney disease Two Phase 2 clinical studies due to report mid-2020: * DMX-200 in FSGS Phase 2a — last patient, last dose: June 2020 * DMX-200 in diabetic kidney disease Phase 2 — last patient last dose: July 2020 iY; Both studies remain on- Patients from both 2017 Pha
Slide 23: Assets 100% owned by Dimerix
For personal use only $ Assets 100% owned by Dimerix 23
Slide 24: For personal use only
For personal use only FY 2020 FSGS Phase 2a study 1st DMX-200 patents Diabetic Kidney Complete GMP DMX-700 added to 2nd Innovation Connections fully recruited announced in Europe Disease Phase 2 study commercial batch pipeline Grant awarded Jul19 Jul19 fully recruited manufacture Oct19 Oct19 Sep19 O
Slide 25: End of Presentation
DIMERIX (ASX:DXB) End of Presentation @ Dimerix